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method should be used instead of OLS to avoid selection bias
due to censoring.
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OBJECTIVES: A survey was conducted to compare smoking
behavior and self-reported respiratory symptoms of persons with
and without diagnosed COPD. METHODS: In a study con-
ducted within the Saskatchewan Health database, persons over
40 years old with diagnosed COPD, emphysema or chronic
bronchitis and at least two bronchodilator prescriptions within
six months of respiratory diagnosis were identiﬁed (N = 11,493).
An age/gender matched comparison group without COPD,
asthma or any respiratory diagnoses or medications was identi-
ﬁed (N = 22,986). A survey was mailed to an age/gender strati-
ﬁed random sample of 4002 subjects, half from the COPD group
and half from the comparison group. RESULTS: The response
rate was 41% among COPD patients and 40% in the compari-
son group. Among those with COPD, 80% had ever smoked,
compared with 53% of those without COPD (OR: 4.01, CI:
3.19–5.04). Among ever smokers, 16% of COPD and 11% of
non-COPD subjects were current smokers (OR: 1.58, CI:
1.09–2.29). A large proportion of the smokers, 73% in the
COPD group and 49% in the non-COPD group, had smoked
for over 30 years. Odds ratios for self-reported symptoms of
COPD comparing the COPD cohort to non-COPD were 11.0
(CI: 8.1–15.1) for persistent cough, 10.4 (CI: 8.1–13.6) for
phlegm with cough, 25.1 (CI: 18.5–34.0) for wheezing, and 18.5
(CI: 13.8–24.8) for shortness of breath with mild exercise.
Among the subjects classiﬁed as non-COPD, 20% reported
having any of the above-mentioned respiratory symptoms and
only 2% reported having all four symptoms. CONCLUSIONS:
Persons with diagnosed COPD are more likely to have been
smokers in the past and had a longer smoking history than
persons without COPD. Crude measures such as the proportion
that ever smoked may not capture substantial differences in
smoking-related illness. Self-reported respiratory symptoms sup-
ported the categorization of COPD vs. non-COPD made using
administrative data.
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OBJECTIVES: To determine the inﬂuence of anemia on hospi-
talization and mortality in elderly patients with chronic obstruc-
tive pulmonary disease (COPD) and chronic kidney disease
(CKD). METHODS: We identiﬁed ambulatory patients over age
65 who had at least one outpatient hemoglobin lab between
1998 to 2002. Patients were identiﬁed using a medical record
data repository from a large health care system in Western Penn-
sylvania. COPD was identiﬁed using ICD-9 coding and CKD was
deﬁned as having at least 2 GFR measurements <60ml/min sep-
arated by at least 3 weeks. Demographic, comorbidity, labora-
tory, and visit data were collected. Anemia was deﬁned by WHO
criteria as a hemoglobin <13g/dL in males and <12g/dL in
females. Cox proportional hazard models were used to estimate
the hazard ratio of ﬁrst hospitalization and death by adjusting
for demographics and comorbidities. Hazard ratios of anemic
and non-anemic cohorts were compared. RESULTS: There were
895 elderly patients (47% male; 87% white) identiﬁed with
COPD and CKD. Comorbidities included hypertension in 86%,
heart failure in 78%, and diabetes in 54% of patients. Males had
higher rates of anemia (58% versus 49%, p = 0.006). Compared
to non-anemic patients, those with anemia had a higher rate of
hospitalization within 1 year (hazard ratio = 1.34, 95% CI: 1.14,
1.57). Mean inpatient days during the study timeframe were
higher for anemic patients (51 verses 44 days, p = 0.03). The
adjusted hazard ratio for all-cause mortality in anemic patients
was 1.52 (95% CI: 1.18, 1.99). Mean survival time for anemic
patients was 44.5 months and for non-anemic patients was 48.9
months (p = 0.003). CONCLUSIONS: The results of this study
suggest that anemia is associated with a signiﬁcant increase in
the risk of hospitalization and death in elderly patients with
COPD and CKD after adjusting for other comorbidities. The
effect of anemia management on these outcomes should be eval-
uated in prospective clinical trials.
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OBJECTIVES: In preparation for exploring the potential cost-
effectiveness of inhaled corticosteroids (ICS) for the treatment of
chronic obstructive pulmonary disease (COPD), we explored the
costs and outcomes of patients with COPD in the presence of
missing data. METHODS: Using data on 751 patients enrolled
in the ISOLDE randomized controlled trial that received either
ﬂuticasone propionate or placebo, the outcomes studied were
COPD exacerbations, successfully treated weeks, rate of decline
in FEV1, costs, survival and health status. In line with the orig-
inal clinical analysis, costs and outcomes were estimated using a
hierarchical multilevel model assuming data were missing at
random. Further analyses explored the use of quality-adjusted
survival techniques for health outcomes as well as multiple impu-
tation methods to address missing data issues. RESULTS: In the
base case analysis we estimated the incremental costs of ICS
versus placebo to be £900 (95% conﬁdence interval (CI): 100;
1700) and the additional effect of 0.59 (CI: 0; 1.3) exacerbations
avoided and 3 (CI: 1.7; 4.5) successfully treated weeks. We
explored the robustness of these results to alternative assump-
tions in extensive sensitivity analysis. While survival was higher
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in the ICS group, the difference in mortality rate was not statis-
tically signiﬁcant (Hazard Ratio: 0.77 CI: 0.52; 1.15). However,
there was a signiﬁcant quality-of-life beneﬁt in favor of ICS.
CONCLUSIONS: Despite a lack of signiﬁcance in survival ben-
eﬁts, joint considerations of quality of life and survival indicate
that ICS could be considered potentially cost-effective. Imputa-
tion methods can be employed to address missing data issues
when the extent of missingness is not too extreme.
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OBJECTIVES: The study objective was to use administrative
claims to create episodes of acute respiratory care as a means of
better understanding the economic burden of acute treatment of
COPD. METHODS: Respiratory-related medical (ICD-9-CM
480.xx–519.xx) and pharmacy claims were extracted from a
managed care database for all patients 30 years of age or more
who were diagnosed with COPD (ICD-9-CM 491.xx, 492.xx,
and 496.xx) between 1997 and 2001. Acute respiratory-related
services were categorized as inpatient treatment, emergency
room (ER) treatment, or an ofﬁce visit combined with an antibi-
otic or oral steroid dispensed within three days of the visit.
Episodes of care were created by continuously combining acute
medical claims until a gap of 14 days or longer were found
between claims. Acute services after such a gap began a new
episode. Each patient was tracked longitudinally and all episodes
during the study period were included. Study measures included
service location, duration, and health plan payments (in 2002
$US). RESULTS: The average age of the 164,566 patients was
68 years, and 50% were male. Patients received more than
510,000 unique acute respiratory medical services; 37% were
inpatient, 22% ER, and 41% ofﬁce visits. These services were
combined to create 385,352 episodes (1.3 unique medical ser-
vices per episode), of which 45% involved inpatient care. The
average duration of episodes involving hospitalization was 10.6
days, with a mean payment of $12,661. These episodes lasted
2.6 days longer and payments were 12% more than individual
hospital stays. Approximately 10–15% of outpatient episodes
involved multiple ER or ofﬁce visits. Mean payments for ofﬁce
visit and ER episodes, including acute drug costs, were $231 and
$841, respectively. CONCLUSIONS: Combining individual
claims for acute respiratory services into episodes of care provide
a more comprehensive estimate of the costs of respiratory exac-
erbations for patients with COPD.
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OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is
the fourth-leading cause of death in the United States and
accounts for about 14 billion dollars annually. This study
assesses the economic burden of COPD in a state health insur-
ance program in terms of medical resources and pharmacother-
apy from a payer perspective. METHODS: Outpatient, hospital
and emergency department (ED) claims with a primary ICD-9
code for chronic bronchitis (491.xx), emphysema (492.xx), and
chronic airways obstruction (496.xx) dated between July 1, 2001
and June 30, 2003 were extracted from the claims database of
a state health insurance program. Unique recipient identiﬁers
obtained from these claims were then used to extract COPD-
related prescription claims. Payer reimbursements were used to
calculate costs. Rates of use of maintenance medications was
assessed for the following therapeutic classes: 1) use of any
inhaled anti-inﬂammatory therapy (inhaled corticosteroids, cro-
molyn, nedocromil, and 2) use of “other” maintenance drugs
such as long-acting beta-agonists, leukotriene modiﬁers, anti-
cholinergics, and theophylline agents. RESULTS: Overall, COPD
prevalence was 52.2/1000 recipients. Of the 7165 recipients
identiﬁed with COPD, 11.8% (N = 848) received inhaled anti-
inﬂammatory drugs, and 19.4% (N = 1389) received “other”
maintenance medications for COPD. The hospitalization rate
was 7.9 hospitalizations/10,000 recipients, at a mean cost of
$1322 (SD = $1025) per visit per recipient (pvpr). The rates of
outpatient and ED use were 112 outpatient visits/1000 recipi-
ents, and 56 ED visits/10,000 recipients, respectively. The mean
cost pvpr for outpatient and ED use was $51 (SD = $72) and
$69 (SD = $80), respectively. The total COPD-related annual
average expenditures to the payer were $10,051,244 of which
prescription use accounted for 95%, followed by outpatient use
(4%), hospitalizations (0.7%), and ED use (0.3%). CONCLU-
SIONS: COPD exerted a signiﬁcant burden on the payer.
Although prescription use accounted for the most dollars, 
hospital use and costs were signiﬁcantly lower than national 
estimates.
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OBJECTIVE: Chronic respiratory illnesses such as asthma and
chronic obstructive pulmonary disease (COPD) not only impact
economic outcomes, but they also impact patients’ health-related
quality of life (HRQL). The objective of this study was to assess
the HRQL in patients with asthma and COPD. METHODS: All
employees receiving health beneﬁts through a state health insur-
ance program constituted the study population. Recipients
having medical claims with a primary ICD-9 code for asthma
(493.xx), chronic bronchitis (491.xx), emphysema (492.xx), or
chronic airways obstruction (496.xx) between July 1st, 2001 and
June 30th, 2003, were selected. These patients were classiﬁed as
having asthma-only, COPD-only, or having both asthma and
COPD, based on ICD9 codes. These patients were mailed the St.
George’s Respiratory Questionnaire (SGRQ), which has been
validated for measuring HRQL in patients with asthma as well
as COPD. The SGRQ consists of 3 subscales: symptoms, activ-
ity, and impacts, as well as a summary score, each ranging from
0 to 100, with higher scores indicating worse HRQL. T-tests and
ANOVAs were used to compare HRQL between the 3 groups.
RESULTS: Overall prevalence of chronic respiratory disease was
69.9/1000 recipients (asthma n = 1493; COPD n = 7165; both
n = 940). Overall survey response rate (RR) was 22.6% (asthma
